SKIN · Injectable
Skin-Glow (GHK-Cu).
Copper peptide for collagen and skin repair
How it works
Class & mechanism.
In short
Skin-Glow combines GHK-Cu, a copper-binding tripeptide studied for collagen, elastin, and tissue repair, with Melanotan-2, a synthetic alpha-MSH analogue studied for melanin-based UV-protective pigmentation. The two peptides act through entirely separate mechanisms — GHK-Cu via gene expression and matrix remodeling, Melanotan-2 via melanocortin receptor activation — and are combined here as a dual-pathway skin protocol rather than a single compound. Both components are currently under FDA PCAC review (Feb 2027) and neither is approved for cosmetic or dermatological use.
Class
Copper-Binding Tripeptide (Tissue Regeneration Signal)
Mechanism
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper chelate found in human plasma, saliva, and urine that functions as a master tissue repair signal. It binds copper(II) with high affinity, and the resulting complex activates a remarkably broad transcriptional program: upregulating ~31% of genes involved in tissue remodeling, antioxidant defense, and stem cell activation, while downregulating ~18% of genes associated with inflammation, oxidative damage, and cancer progression. In skin specifically, GHK-Cu stimulates collagen, elastin, glycosaminoglycan, proteoglycan, and decorin synthesis in fibroblasts; activates matrix metalloproteinase (MMP) remodeling to clear damaged tissue; promotes angiogenesis for tissue repair; and increases keratinocyte and stem cell activity to restore epidermal barrier integrity.
Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.
Did you know
GHK-Cu was discovered in 1973 when a researcher noticed that aging human liver tissue started behaving like young tissue when exposed to a mystery fraction from young blood plasma — and that mystery molecule turned out to be a simple three-amino-acid copper complex your body already makes, that simply declines 60% by age 60.
Benefits
What it does.
May stimulate collagen and elastin production — clinical cosmetic studies report tightened loose skin and reduced appearance of fine lines and deep wrinkles
Genome-wide analysis suggests activity across >300 human genes involved in tissue regeneration, antioxidant defense, and stem cell renewal
Preclinical evidence suggests it may accelerate wound healing, with effects reported in diabetic, ischemic, and chronic wound models across multiple animal studies
Clinical cosmetic studies report reduced hyperpigmentation, improved skin density and firmness, and protection against UV damage
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
What this does not mean
Skin-Glow consists of research chemicals. GHK-Cu and Melanotan-2 are not FDA-approved for skin rejuvenation, pigmentation, wound healing, or any other use, and both compounds are currently under FDA Pharmacy Compounding Advisory Committee (PCAC) review (Feb 2027) regarding their compounding eligibility. Melanotan-2 in particular carries a distinct risk profile — including documented cases of melanocytic naevi changes and is banned by WADA for competitive athletes — and should not be used by anyone with a personal or family history of melanoma or atypical moles. The information on this page is educational and does not constitute medical advice, diagnosis, or treatment. This page does not recommend, endorse, or prescribe any compound for human use. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols or pharmaceutical recommendations.
Genome-wide analysis showed GHK-Cu modulates the expression of over 4,000 human genes — upregulating genes for collagen, antioxidant enzymes, and stem cell markers (p53, integrins), while downregulating inflammation and oncogene pathways.
SOURCE · Pickart & Margolina, Cosmetics (MDPI) 2018; Frontiers in Aging Neuroscience
Clinical cosmetic studies report GHK-Cu tightening loose skin, reversing thinning, improving elasticity, increasing skin density, reducing fine lines and deep wrinkles, and protecting against UV damage — with reproducible results across topical and injectable application forms.
SOURCE · Multiple clinical cosmetic studies (compiled in Pickart review, Biomed Research International 2015)
Plasma GHK-Cu concentrations decline from ~200 ng/mL at age 20 to ~80 ng/mL by age 60 — a 60% reduction that parallels the loss of regenerative capacity, suggesting GHK-Cu depletion is a measurable component of biological skin aging.
SOURCE · Pickart (1973); referenced in GHK-Cu clinical documentation
Protocol
How to use it.
Dosing
Injectable: 1–2 mg (0.03–0.06 mL) subcutaneous injection daily Monday–Friday. Topical: applied to clean skin 1–2x daily; concentration varies by product (typically 1–5%). Topical and injectable routes can be combined for synergistic effect. PK data for individual components: Melanotan-2 has curve-grade pharmacokinetic data available on its product page (including t½, bioavailability, and clearance). GHK-Cu plasma concentration data and PK rationale are on its product page. See each component page for detailed pharmacokinetic profiles.
Cycle
Injectable protocols typically run 8–12 weeks, followed by a 4-week break before reassessment. Topical use can be maintained continuously. Benefits are cumulative — improvements in collagen density and skin quality build over months of consistent use.
Contraindications
When to skip it.
Generally excellent safety profile — GHK-Cu is endogenous and bioidentical. Possible injection site reactions (bruising, temporary redness). Excessive injectable doses may cause temporary skin sensitivity. Avoid in known copper hypersensitivity (rare). Wilson's disease (copper metabolism disorder) is a contraindication for high-dose injectable use.
Always cleared with your concierge before protocol start.
Regulatory Context
FDA compounding status.
| FDA Status | Risk Level | Compounding | Key Date |
|---|---|---|---|
| Mixed — GHK-Cu (Feb 2027 PCAC) + Melanotan II (Feb 2027) | 🟡 Under Review | Both components await Feb 2027 PCAC | PCAC Feb 2027 |
Blend of GHK-Cu and Melanotan II. Both components under Feb 2027 PCAC review. GHK-Cu topical is Category 1 — injectable needs PCAC clearance.
Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.
Pricing
What it costs.
Indicative range for Skin-Glow (GHK-Cu), sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See Skin-Glow (GHK-Cu) pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $104–$156 USD